Fontolizumab

From WikiMD.org
Jump to navigation Jump to search

Fontolizumab (pronunciation: fon-toh-lih-zoo-mab) is a monoclonal antibody designed for the treatment of various autoimmune diseases. It is an experimental drug that has been studied in clinical trials for conditions such as Crohn's disease and rheumatoid arthritis.

Etymology

The name "Fontolizumab" is derived from the Latin word "fontalis," meaning "of a spring," and "zumab," a common suffix for humanized monoclonal antibodies.

Mechanism of Action

Fontolizumab works by targeting and neutralizing interferon gamma, a cytokine that plays a crucial role in inflammation and immune response. By blocking the action of interferon gamma, fontolizumab can help reduce inflammation and alleviate symptoms in patients with autoimmune diseases.

Clinical Trials

Fontolizumab has been tested in several clinical trials. In a Phase II trial for Crohn's disease, the drug showed promise in reducing symptoms and improving quality of life for patients. However, further research is needed to confirm these results and determine the long-term safety and efficacy of fontolizumab.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski